In a target trial emulation using N3C data, adults prescribed metformin within six days of SARS-CoV-2 infection had about half the risk of long COVID or death within six months.
|Videos|June 24, 2020
Contagion Live News Network: Coronavirus Guidelines Discourage Hydroxychloroquine Outside Trials
Author(s)Contagion® Editorial Staff
Video briefing on the day's top infectious disease news.
Advertisement
In light of evolving knowledge about SARS-CoV-2, the Infectious Diseases Society of America (IDSA) has updated guidelines for treating
Given research into SARS-CoV-2 is taking place at unprecedented speed, the panel of IDSA experts had to decide on current best practices using science which is still in motion.
Recent updates include:
1. New recommendations on the use of remdesivir.
2. Revised recommendations on hydroxychloroquine and hydroxychloroquine/azithromycin combination therapy.
3. New recommendations for famotidine.
4. Revised recommendations concerning convalescent plasma for treatment of COVID-19.
In other news, a recent review of electronic health data revealed a 42% drop in emergency department visits during 4 weeks of the pandemic. Public health officials are concerned that fear over the coronavirus has led to patients delaying care for life-threatening illness.
And lastly, we
Advertisement
Related to this article
Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute infection and more than a quarter had completely remitted, in a large prospective cohort study.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
2
Half of Long COVID Patients Substantially Improve Within 3 years
3
From Pathogen to Infectious Disease Diagnosis: Reflex Testing Targets Hepatitis D Gap
4
Fungal-WHAT? Updates to the WHO Antifungal Pipeline
5